EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption

Rachael Thomas iD, Claire A Wiley, Emma L Droste, James Robertson iD, Brant A Inman iD, Matthew Breen iD

PLOS Genetics · 2023

DOI: 10.1371/journal.pgen.1010575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, 2023. Verfasst von Rachael Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, MAP Kinase Kinase 1, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: College of Veterinary Medicine, North Carolina State University, NCSU Cancer Genomics Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UD V595E specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UD V595E specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UD V595E cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMAP Kinase Kinase 1Urinary Bladder NeoplasmsCarcinoma, Transitional CellAnimalsDogsExome SequencingMAP Kinase Signaling SystemDNA Copy Number VariationsSequence DeletionMaleFemale

Substanzen

Proto-Oncogene Proteins B-rafMAP Kinase Kinase 1

Autor:innen und Institutionen

  • Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America.
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, United States of America.
  • Office of Research (Biostatistics), College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America.
  • Department of Surgery, School of Medicine, Duke University, Durham, North Carolina, United States of America.
  • Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
  • Center for Human Health and the Environment, North Carolina State University, Raleigh, North Carolina, United States of America.

ORCID-Profile: Rachael Thomas, James Robertson, Brant A Inman, Matthew Breen

Förderung

  • College of Veterinary Medicine, North Carolina State University
  • NCSU Cancer Genomics Fund

Zitieren

APA

Thomas, R., Wiley, C. A., Droste, E. L., Robertson, J., Inman, B. A., & Breen, M. (2023). Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1010575

Vancouver

Thomas R, Wiley CA, Droste EL, Robertson J, Inman BA, Breen M. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. PLOS Genetics. 2023. doi:10.1371/journal.pgen.1010575

BibTeX
@article{Thomas2023,
  author = {Thomas, Rachael and Wiley, Claire A and Droste, Emma L and Robertson, James and Inman, Brant A and Breen, Matthew},
  title = {Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption},
  journal = {PLOS Genetics},
  year = {2023},
  doi = {10.1371/journal.pgen.1010575}
}
Kostenlos starten →